Update | Ordinary Index Rebalancing in the Solactive Pharma Breakthrough Value Index | March 2021

Update to the announcement from 08.03.2020. In the ordinary rebalance the following updated composition will be implemented effective open 22.03.2021:

ABBVIE INC
ALEXION PHARMACEUTICALS INC
ALNYLAM PHARMACEUTICALS INC
BEIGENE LTD-ADR
BIOGEN INC
BIOMARIN PHARMACEUTICAL INC
BRISTOL-MYERS SQUIBB CO
CHUGAI PHARMACEUTICAL CO LTD ORD
CSL LTD ORD
EISAI
EMERGENT BIOSOLUTIONS INC
ENDO INTERNATIONAL PLC
GENMAB A/S
GRIFOLS SA CLASS A
H LUNDBECK AS
HALOZYME THERAPEUTICS INC
HORIZON THERAPEUTICS PLC
INCYTE CORP
IONIS PHARMACEUTICALS INC
IPSEN SA
JAZZ PHARMACEUTICALS PLC
JOHNSON & JOHNSON
KYOWA KIRIN CO LTD
LIGAND PHARMACEUTICALS INC
NEKTAR THERAPEUTICS
NIPPON SHINYAKU CO LTD
NOVARTIS AG
PHARMA MAR SA
ROCHE HOLDING AG
SANOFI SA
SAREPTA THERAPEUTICS INC
SEAGEN INC
SWEDISH ORPHAN BIOVITRUM AB
ULTRAGENYX PHARMACEUTICAL INC
UNITED THERAPEUTICS CORP
VERTEX PHARMACEUTICALS INC